Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Jantus-Lewintre E. ; Massutí Sureda B. ; González Larriba J.L. ; Rodríguez-Abreu D. ; Juan O. ; Blasco A. ; Dómine M. ; Provencio Pulla M. ; Garde J. ; Álvarez R. ; Maestu I. ; Pérez de Carrión R. ; Artal Cortés, Á. (Universidad de Zaragoza) ; Rolfo C. ; de Castro J. ; Guillot M. ; Oramas J. ; de las Peñas R. ; Ferrera L. ; Martínez N. ; Serra Ò. ; Rosell R. ; Camps C. ; on behalf of Grupo Espanol de Cancer de Pulmon (GECP)

Resumen: Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy. © Copyright © 2021 Jantus-Lewintre, Massutí Sureda, González Larriba, Rodríguez-Abreu, Juan, Blasco, Dómine, Provencio Pulla, Garde, Álvarez, Maestu, Pérez de Carrión, Artal, Rolfo, de Castro, Guillot, Oramas, de las Peñas, Ferrera, Martínez, Serra, Rosell and Camps.

Idioma: Inglés

DOI: 10.3389/fonc.2021.695038

Año: 2021

Publicado en: Frontiers in Oncology 11 (2021), 695038 [11 pp]
ISSN: 2234-943X

Factor impacto JCR: 5.738 (2021)

Categ. JCR: ONCOLOGY rank: 78 / 245 = 0.318 (2021) - Q2 - T1

Factor impacto CITESCORE: 4.5 - Medicine (Q2) - Biochemistry, Genetics and Molecular Biology (Q3)

Factor impacto SCIMAGO: 1.291 - Oncology (Q1) - Cancer Research (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)